58 related articles for article (PubMed ID: 20636881)
1. Effects of K openers on the QT prolongation induced by HERG-blocking drugs in guinea-pigs.
Testai L; Cecchetti V; Sabatini S; Martelli A; Breschi MC; Calderone V
J Pharm Pharmacol; 2010 Jul; 62(7):924-30. PubMed ID: 20636881
[TBL] [Abstract][Full Text] [Related]
2. Modulation of norepinephrine release by ATP-dependent K(+)-channel activators and inhibitors in guinea-pig and human isolated right atrium.
Oe K; Sperlágh B; Sántha E; Matkó I; Nagashima H; Foldes FF; Vizi ES
Cardiovasc Res; 1999 Jul; 43(1):125-34. PubMed ID: 10536697
[TBL] [Abstract][Full Text] [Related]
3. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury.
Lee SH; Yang MK; Lim JH; Seo HW; Yi KY; Yoo SE; Lee BH; Won HS; Lee CS; Choi WS; Shin HS
Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS
J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and histochemical distinctions between molecularly defined sarcolemmal KATP channels and native cardiac mitochondrial KATP channels.
Hu H; Sato T; Seharaseyon J; Liu Y; Johns DC; O'Rourke B; Marbán E
Mol Pharmacol; 1999 Jun; 55(6):1000-5. PubMed ID: 10347240
[TBL] [Abstract][Full Text] [Related]
6. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
7. Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene-without QT interval prolongation.
Yuill KH; Borg JJ; Ridley JM; Milnes JT; Witchel HJ; Paul AA; Kozlowski RZ; Hancox JC
Biochem Biophys Res Commun; 2004 May; 318(2):556-61. PubMed ID: 15120636
[TBL] [Abstract][Full Text] [Related]
8. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
9. In vivo effects of the IKr agonist NS3623 on cardiac electrophysiology of the guinea pig.
Hansen RS; Olesen SP; Rønn LC; Grunnet M
J Cardiovasc Pharmacol; 2008 Jul; 52(1):35-41. PubMed ID: 18594476
[TBL] [Abstract][Full Text] [Related]
10. Modulation of ATP-sensitive K+ channel activity and contractile behavior in mammalian ventricle by the potassium channel openers cromakalim and RP49356.
Ripoll C; Lederer WJ; Nichols CG
J Pharmacol Exp Ther; 1990 Nov; 255(2):429-35. PubMed ID: 2243335
[TBL] [Abstract][Full Text] [Related]
11. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking.
Wang L; Wible BA; Wan X; Ficker E
J Pharmacol Exp Ther; 2007 Feb; 320(2):525-34. PubMed ID: 17095614
[TBL] [Abstract][Full Text] [Related]
12. Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval.
Cheng HC; Incardona J; McCullough B
J Pharmacol Toxicol Methods; 2006; 54(3):278-87. PubMed ID: 16507347
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia.
Grover GJ
J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S18-27. PubMed ID: 7898104
[TBL] [Abstract][Full Text] [Related]
14. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
Nielsen-Kudsk JE
Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
[TBL] [Abstract][Full Text] [Related]
15. Pentamidine-induced long QT syndrome and block of hERG trafficking.
Kuryshev YA; Ficker E; Wang L; Hawryluk P; Dennis AT; Wible BA; Brown AM; Kang J; Chen XL; Sawamura K; Reynolds W; Rampe D
J Pharmacol Exp Ther; 2005 Jan; 312(1):316-23. PubMed ID: 15340016
[TBL] [Abstract][Full Text] [Related]
16. QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. II.
Testai L; Breschi MC; Martinotti E; Calderone V
J Appl Toxicol; 2007; 27(3):270-5. PubMed ID: 17265420
[TBL] [Abstract][Full Text] [Related]
17. Validation of visualized transgenic zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk candidates.
Wen D; Liu A; Chen F; Yang J; Dai R
J Appl Toxicol; 2012 Oct; 32(10):834-42. PubMed ID: 22744888
[TBL] [Abstract][Full Text] [Related]
18. [HERG K+ channel, the target of anti-arrhythmias drugs].
Guan FY; Yang SJ
Yao Xue Xue Bao; 2007 Jul; 42(7):687-91. PubMed ID: 17882949
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human ether-a-go-go-related gene K+ channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine.
Choi SY; Koh YS; Jo SH
J Pharmacol Exp Ther; 2005 May; 313(2):888-95. PubMed ID: 15722405
[TBL] [Abstract][Full Text] [Related]
20. Sarcolemmal cardiac K(ATP) channels as a target for the cardioprotective effects of the fluorine-containing pinacidil analogue, flocalin.
Voitychuk OI; Strutynskyi RB; Yagupolskii LM; Tinker A; Moibenko OO; Shuba YM
Br J Pharmacol; 2011 Feb; 162(3):701-11. PubMed ID: 20942816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
